Results 241 to 250 of about 242,978 (299)
Weight Loss With GLP‐1 Agonists in Nondiabetic Adults: Systematic Review and Network Meta‐Analysis
Obesity, EarlyView.ABSTRACT Objective Two glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) (semaglutide and liraglutide) and one dual agonist (tirzepatide) are FDA‐approved for weight loss in adults with obesity without type 2 diabetes mellitus. This systematic review and network meta‐analysis aims to compare the efficacy of these agents against each other.
Michael Lim +3 more
wiley +1 more source
Effectiveness and Safety of Setmelanotide in a Patient With a Heterozygous PCSK1 Deficiency
Obesity, EarlyView.ABSTRACT Setmelanotide, a melanocortin 4 receptor (MC4R) agonist, is a promising pharmacological treatment option for people with rare monogenic obesity conditions affecting the leptin‐melanocortin signaling pathway, including proprotein convertase subtilisin/kexin type 1 (PCSK1) gene mutations.
Ellina Lytvyak +2 more
wiley +1 more source
People and Nature, EarlyView.Abstract Managing wildfire risk requires consideration of complex and uncertain scientific evidence as well as trade‐offs between different values and goals. Conflicting perspectives on what values and goals are most important, what ought to be done and what trade‐offs are acceptable complicate those decisions.
Pele J. Cannon, Sarah Clement
wiley +1 more source
Pediatric Discovery, EarlyView.Through network pharmacology and molecular docking, it has been discovered that CA can target MAOB, among other proteins, to exert a therapeutic effect in IBS. In vivo, CA lowered visceral hypersensitivity, anxiety and depression‐like behaviors, and fecal water content, highlighting its therapeutic potential for IBS via anti‐inflammatory pathways ...
Qingyang Yu +4 more
wiley +1 more source
Pediatric Investigation, EarlyView.Monogenic and syndromic obesity in children often arises from defects in the leptin–melanocortin pathway. Understanding these rare genetic causes not only clarifies mechanisms of appetite regulation but also enables precision therapies, offering hope beyond lifestyle interventions.
Hadel Khalil +2 more
wiley +1 more source
Portal Hypertension &Cirrhosis, EarlyView.Metabolic dysfunction‐associated steatotic liver disease (MASLD) is a chronic liver disease. Research into a feasible, rapid, and effective assessment method is crucial for evaluating the therapeutic effects of semaglutide in MASLD. This prospective study utilized ultrasound‐derived fat fraction measurement and fat‐to‐muscle ratio to evaluate hepatic ...
Yunlin Huang +10 more
wiley +1 more source
Traditional Chinese Medicine for lung cancer: Mechanisms, clinical evidence, and future perspectives
Precision Medical Sciences, EarlyView.Graphical abstract represents the risk factors for lung cancer, TCM efficacy and clinical outcomes to future challenges. Abstract Lung cancer remains a leading cause of global cancer mortality. Despite advances in conventional treatments such as surgery, chemotherapy, targeted therapy, and immunotherapy, challenges including drug resistance, toxicity ...
Zhangdeng Chen, Liujun Bao
wiley +1 more source
Ashwagandha: Is It Safe? Part 1: A Regulatory Review
Phytotherapy Research, EarlyView.ABSTRACT Over the last decade, ashwagandha (Withania somnifera (L.) Dunal, AS) has been brought under increasing scrutiny by EU regulators regarding its safety for the use in food supplements, culminating in a recent recommendation for an Article 8 procedure according to Regulation (EC) No. 1925/2006 in the European Union (EU).
T. Brendler +5 more
wiley +1 more source
Consultation on the future of the right to request ‘time to train’ regulations: government response [PDF]
, 2011 core
Can Reprogramming Taste Modulate Excess Food Intake?
Obesity, EarlyView.
Kerstin Rohde‐Zimmermann +1 more
wiley +1 more source